-+ 0.00%
-+ 0.00%
-+ 0.00%

HCW Biologics Q3 net loss narrows 29% to $3.22 million

PUBT·11/16/2026 13:17:15
Listen to the news
HCW Biologics Q3 net loss narrows 29% to $3.22 million
  • HCW Biologics’ third-quarter 2026 net loss narrowed 29% year over year to $3.22 million.
  • Revenues more than tripled year over year to $55,463.
  • November debt financing secured up to $10 million, including $3 million received at closing before transaction costs.
  • HCW9302 Phase 1 completion and recommended Phase 2 dose determination are expected in the first quarter of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HCW Biologics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611160815PRIMZONEFULLFEED9878055) on November 16, 2026, and is solely responsible for the information contained therein.